midodrine has been researched along with Acute Kidney Injury in 6 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Acute Kidney Injury: Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Midodrine along with albumin infusion, is helpful in the secondary prophylaxis of HRS-AKI and reduces the number of ascites tap." | 8.02 | Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. ( Arora, A; Bansal, N; Kumar, A; Puri, P; Sharma, P; ShriHari, AA; Singla, V, 2021) |
| "Midodrine along with albumin infusion, is helpful in the secondary prophylaxis of HRS-AKI and reduces the number of ascites tap." | 4.02 | Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. ( Arora, A; Bansal, N; Kumar, A; Puri, P; Sharma, P; ShriHari, AA; Singla, V, 2021) |
| "The hepatorenal syndrome is a well-recognized complication of advanced cirrhosis and is usually associated with an accelerated course to death unless liver transplantation is performed." | 2.53 | Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. ( Bertino, G; Crisafulli, E; Demma, S; Koukias, N; Privitera, G; Purrello, F; Spadaro, L; Tsochatzis, EA, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Flamm, SL | 1 |
| Wong, F | 1 |
| Ahn, J | 1 |
| Kamath, PS | 1 |
| Sharma, P | 1 |
| Puri, P | 1 |
| Bansal, N | 1 |
| Singla, V | 1 |
| Kumar, A | 1 |
| ShriHari, AA | 1 |
| Arora, A | 1 |
| Velez, JC | 1 |
| Kadian, M | 1 |
| Taburyanskaya, M | 1 |
| Bohm, NM | 1 |
| Delay, TA | 1 |
| Karakala, N | 1 |
| Rockey, DC | 1 |
| Nietert, PJ | 1 |
| Goodwin, AJ | 1 |
| Whelan, TP | 1 |
| Bertino, G | 1 |
| Privitera, G | 1 |
| Purrello, F | 1 |
| Demma, S | 1 |
| Crisafulli, E | 1 |
| Spadaro, L | 1 |
| Koukias, N | 1 |
| Tsochatzis, EA | 1 |
| Dong, T | 1 |
| Aronsohn, A | 1 |
| Gautham Reddy, K | 1 |
| Te, HS | 1 |
| Esrailian, E | 1 |
| Runyon, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients[NCT05621005] | Phase 2 | 104 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for midodrine and Acute Kidney Injury
| Article | Year |
|---|---|
AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
Topics: Acute Kidney Injury; Albumins; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Creat | 2022 |
Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.
Topics: Acute Kidney Injury; Adrenal Insufficiency; Ascites; Creatinine; Evidence-Based Medicine; Hepatorena | 2016 |
4 other studies available for midodrine and Acute Kidney Injury
| Article | Year |
|---|---|
Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites.
Topics: Acute Kidney Injury; Albumins; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Pi | 2021 |
Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure.
Topics: Acute Kidney Injury; Aged; Arterial Pressure; Creatinine; End Stage Liver Disease; Female; Hepatoren | 2015 |
Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis.
Topics: Acute Kidney Injury; Aged; Anti-Infective Agents; Case-Control Studies; End Stage Liver Disease; Fem | 2016 |
Alcoholic cirrhosis-associated hepatorenal syndrome treated with vasoactive agents.
Topics: Acute Kidney Injury; Adult; Albumins; Gastrointestinal Hemorrhage; Hepatitis, Alcoholic; Humans; Iso | 2006 |